These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37916709)

  • 21. Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
    Spencer SJ; Guzauskas GF; FeLizzi F; Launonen A; Dawson K; Veenstra DL; Masaquel A
    J Manag Care Spec Pharm; 2021 May; 27(5):615-624. PubMed ID: 33586513
    [No Abstract]   [Full Text] [Related]  

  • 22. Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
    Moreno-Martínez E; De la Serna-Torroba J; Escudero-Vilaplana V; Hernández-Rivas JÁ; Sánchez-Cuervo M; Sánchez-Hernández R
    Farm Hosp; 2022 Apr; 46(3):121-132. PubMed ID: 36183205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
    Pott C; Sehn LH; Belada D; Gribben J; Hoster E; Kahl B; Kehden B; Nicolas-Virelizier E; Spielewoy N; Fingerle-Rowson G; Harbron C; Mundt K; Wassner-Fritsch E; Cheson BD
    Leukemia; 2020 Feb; 34(2):522-532. PubMed ID: 31462735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-risk follicular lymphoma: Treatment options.
    Kahl B
    Hematol Oncol; 2021 Jun; 39 Suppl 1():94-99. PubMed ID: 34105813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
    Franceschini E; Pellegrino M; Todisco V; Dolci G; Bettelli F; Meschiari M; Bedini A; Fregni-Serpini G; Grottola A; Guaraldi G; Pecorari M; Sarti M; Luppi M; Perno CF; Mussini C
    Infection; 2023 Oct; 51(5):1577-1581. PubMed ID: 37076752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
    Morschhauser F; Salles G; Le Gouill S; Tilly H; Thieblemont C; Bouabdallah K; Fabiani B; Ménard C; Tarte K; Cartron G; Houot R
    Blood; 2018 Oct; 132(14):1486-1494. PubMed ID: 30068505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
    Thielen FW; Büyükkaramikli NC; Riemsma R; Fayter D; Armstrong N; Wei CY; Huertas Carrera V; Misso K; Worthy G; Kleijnen J; Corro Ramos I
    Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
    Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
    J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Standard treatment and future perspectives for follicular lymphoma].
    Kameoka Y
    Rinsho Ketsueki; 2022; 63(9):1135-1144. PubMed ID: 36198539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
    Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
    Ann Hematol; 2017 Feb; 96(2):253-259. PubMed ID: 27900446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obinutuzumab in follicular lymphoma.
    Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
    Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine.
    Kuriyama K; Kitamura Y; Tsuji T; Nishikawa R; Nagata H; Ohshiro M; Sugitani M; Hirakawa Y; Matsumoto Y; Iwai T; Uchiyama H
    Curr Probl Cancer; 2022 Apr; 46(2):100813. PubMed ID: 34844771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.
    Morschhauser F; Ghosh N; Lossos IS; Palomba ML; Mehta A; Casasnovas O; Stevens D; Katakam S; Knapp A; Nielsen T; McCord R; Salles G
    Blood Cancer J; 2021 Aug; 11(8):147. PubMed ID: 34417444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.
    Hamadani M; Coleman M; Boccia R; Duras J; Hutchings M; Zinzani PL; Cordoba R; Oreiro MB; Williams V; Liu H; Stouffs M; Langmuir P; Sancho JM
    Hematol Oncol; 2023 Dec; 41(5):848-857. PubMed ID: 37496298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group.
    Fujiwara Y; Urata T; Niiya D; Yano T; Nawa Y; Yoshida I; Imai T; Sunami K; Fujii S; Ennishi D; Maeda Y; Hiramatsu Y
    Int J Hematol; 2022 Jun; 115(6):811-815. PubMed ID: 35583725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial.
    Qin Y; Song Y; Shen Z; Du X; Ji W; Hsu W; Zhu J; Shi Y
    Cancer Commun (Lond); 2018 May; 38(1):31. PubMed ID: 29843792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies.
    Kawasaki N; Yamashita-Kashima Y; Fujimura T; Yoshiura S; Harada N; Kondoh O; Yoshimura Y
    Mol Biol Rep; 2022 Jun; 49(6):4421-4433. PubMed ID: 35218445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.